Targeting the SR-B1 Receptor As a Gateway for Cancer Therapy and Imaging

Overview

Journal Front Pharmacol

Date 2016 Dec 27

PMID 28018216

Citations 50

Authors

Linda K Mooberry

Nirupama A Sabnis

Marlyn Panchoo

Bhavani Nagarajan

Andras G Lacko

Affiliations

Soon will be listed here.

Abstract

Malignant tumors display remarkable heterogeneity to the extent that even at the same tissue site different types of cells with varying genetic background may be found. In contrast, a relatively consistent marker the scavenger receptor type B1 (SR-B1) has been found to be consistently overexpressed by most tumor cells. Scavenger Receptor Class B Type I (SR-BI) is a high density lipoprotein (HDL) receptor that facilitates the uptake of cholesterol esters from circulating lipoproteins. Additional findings suggest a critical role for SR-BI in cholesterol metabolism, signaling, motility, and proliferation of cancer cells and thus a potential major impact in carcinogenesis and metastasis. Recent findings indicate that the level of SR-BI expression correlate with aggressiveness and poor survival in breast and prostate cancer. Moreover, genomic data show that depending on the type of cancer, high or low SR-BI expression may promote poor survival. This review discusses the importance of SR-BI as a diagnostic as well as prognostic indicator of cancer to help elucidate the contributions of this protein to cancer development, progression, and survival. In addition, the SR-B1 receptor has been shown to serve as a potential gateway for the delivery of therapeutic agents when reconstituted high density lipoprotein nanoparticles are used for their transport to cancer cells and tumors. Opportunities for the development of new technologies, particularly in the areas of cancer therapy and tumor imaging are discussed.

Citing Articles

Encapsulation and Delivery of the Kinase Inhibitor PIK-75 by Organic Core High-Density Lipoprotein-Like Nanoparticles Targeting Scavenger Receptor Class B Type 1.

Rink J, Lin A, Calvert A, Kwon D, Moxley A, Henrich S ACS Appl Mater Interfaces. 2024; 17(1):363-373.

PMID: 39688216 PMC: 11784712. DOI: 10.1021/acsami.4c15472.

Why make it if you can take it: review on extracellular cholesterol uptake and its importance in breast and ovarian cancers.

Lauridsen A, Skorda A, Winther N, Bay M, Kallunki T J Exp Clin Cancer Res. 2024; 43(1):254.

PMID: 39243069 PMC: 11378638. DOI: 10.1186/s13046-024-03172-y.

Reconstituted HDL ameliorated renal injury of diabetic kidney disease in mice.

Tao Y, Lacko A, Sabnis N, Das-Earl P, Ibrahim D, Crowe N Physiol Rep. 2024; 12(15):e16179.

PMID: 39107084 PMC: 11303015. DOI: 10.14814/phy2.16179.

The Pleiotropic Effects of Lipid-Modifying Interventions: Exploring Traditional and Emerging Hypolipidemic Therapies.

Kounatidis D, Tentolouris N, Vallianou N, Mourouzis I, Karampela I, Stratigou T Metabolites. 2024; 14(7).

PMID: 39057711 PMC: 11278853. DOI: 10.3390/metabo14070388.

Adaptations of membrane trafficking in cancer and tumorigenesis.

Evergren E, Mills I, Kennedy G J Cell Sci. 2024; 137(10).

PMID: 38770683 PMC: 11166456. DOI: 10.1242/jcs.260943.

References

Counsell R, Pohland R . Lipoproteins as potential site-specific delivery systems for diagnostic and therapeutic agents. J Med Chem. 1982; 25(10):1115-20. DOI: 10.1021/jm00352a001. View

Rotheneder M, Kostner G . Effects of low- and high-density lipoproteins on the proliferation of human breast cancer cells in vitro: differences between hormone-dependent and hormone-independent cell lines. Int J Cancer. 1989; 43(5):875-9. DOI: 10.1002/ijc.2910430523. View

Lopez D, McLean M . Sterol regulatory element-binding protein-1a binds to cis elements in the promoter of the rat high density lipoprotein receptor SR-BI gene. Endocrinology. 1999; 140(12):5669-81. DOI: 10.1210/endo.140.12.7220. View

Kypreos K, Gkizas S, Rallidis L, Karagiannides I . HDL particle functionality as a primary pharmacological target for HDL-based therapies. Biochem Pharmacol. 2013; 85(11):1575-8. DOI: 10.1016/j.bcp.2013.03.004. View

Arenas M, Lobo M, Caso E, Huerta L, Paniagua R, Martin-Hidalgo M . Normal and pathological human testes express hormone-sensitive lipase and the lipid receptors CLA-1/SR-BI and CD36. Hum Pathol. 2004; 35(1):34-42. DOI: 10.1016/j.humpath.2003.08.015. View

Mooberry L, Nair M, Paranjape S, McConathy W, Lacko A . Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier. J Drug Target. 2009; 18(1):53-8. DOI: 10.3109/10611860903156419. View

Lou B, Liao X, Wu M, Cheng P, Yin C, Fei Z . High-density lipoprotein as a potential carrier for delivery of a lipophilic antitumoral drug into hepatoma cells. World J Gastroenterol. 2005; 11(7):954-9. PMC: 4250784. DOI: 10.3748/wjg.v11.i7.954. View

Connelly M . SR-BI-mediated HDL cholesteryl ester delivery in the adrenal gland. Mol Cell Endocrinol. 2008; 300(1-2):83-8. DOI: 10.1016/j.mce.2008.09.011. View

Yang S, Damiano M, Zhang H, Tripathy S, Luthi A, Rink J . Biomimetic, synthetic HDL nanostructures for lymphoma. Proc Natl Acad Sci U S A. 2013; 110(7):2511-6. PMC: 3574906. DOI: 10.1073/pnas.1213657110. View

10.

Frias J, Williams K, Fisher E, Fayad Z . Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc. 2004; 126(50):16316-7. DOI: 10.1021/ja044911a. View

11.

Alaupovic P, Lee D, McConathy W . Studies on the composition and structure of plasma lipoproteins. Distribution of lipoprotein families in major density classes of normal human plasma lipoproteins. Biochim Biophys Acta. 1972; 260(4):689-707. View

12.

Fischer N, Weilhammer D, Dunkle A, Thomas C, Hwang M, Corzett M . Evaluation of nanolipoprotein particles (NLPs) as an in vivo delivery platform. PLoS One. 2014; 9(3):e93342. PMC: 3968139. DOI: 10.1371/journal.pone.0093342. View

13.

Atzori L, Mereu R, Satta G, Macis M, Congia M, Tedde A . Serum lipoproteins and cancer. Nutr Metab Cardiovasc Dis. 2008; 19(3):218-25. DOI: 10.1016/j.numecd.2008.06.002. View

14.

Hu Z, Shen W, Kraemer F, Azhar S . MicroRNAs 125a and 455 repress lipoprotein-supported steroidogenesis by targeting scavenger receptor class B type I in steroidogenic cells. Mol Cell Biol. 2012; 32(24):5035-45. PMC: 3510537. DOI: 10.1128/MCB.01002-12. View

15.

Kuai R, Li D, Chen Y, Moon J, Schwendeman A . High-Density Lipoproteins: Nature's Multifunctional Nanoparticles. ACS Nano. 2016; 10(3):3015-41. PMC: 4918468. DOI: 10.1021/acsnano.5b07522. View

16.

Bravi F, Scotti L, Bosetti C, Talamini R, Negri E, Montella M . Self-reported history of hypercholesterolaemia and gallstones and the risk of prostate cancer. Ann Oncol. 2006; 17(6):1014-7. DOI: 10.1093/annonc/mdl080. View

17.

Lacko A, Sabnis N, Nagarajan B, McConathy W . HDL as a drug and nucleic acid delivery vehicle. Front Pharmacol. 2015; 6:247. PMC: 4620406. DOI: 10.3389/fphar.2015.00247. View

18.

Sabnis N, Nair M, Israel M, McConathy W, Lacko A . Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles. Int J Nanomedicine. 2012; 7:975-83. PMC: 3289451. DOI: 10.2147/IJN.S28029. View

19.

Pan B, Ren H, He Y, Lv X, Ma Y, Li J . HDL of patients with type 2 diabetes mellitus elevates the capability of promoting breast cancer metastasis. Clin Cancer Res. 2012; 18(5):1246-56. DOI: 10.1158/1078-0432.CCR-11-0817. View

20.

Besler C, Luscher T, Landmesser U . Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease. EMBO Mol Med. 2012; 4(4):251-68. PMC: 3376856. DOI: 10.1002/emmm.201200224. View